Roche/Genentech’s Second Move to Protect Lucentis Franchise

With its patents on Lucentis set to expire in a few years and clinical trials of at least three Lucentis biosimilars underway, Roche’s recent acquisition of ForSight VISION4 is seen by many as the latest strategic move to protect its Lucentis franchise for the foreseeable future. The ForSight VISION4 acquisition gives Roche and its subsidiary,…

Read More

Eye on Five – January Edition

OIS-Eye-On-Five

Alcon Turnaround Has Novartis Exploring Spin-off With its Alcon turnaround plans on track, Novartis AG revealed it is exploring options that include spinning off Alcon or issuing an IPO for the eye-care unit – or even keeping it. Alcon lost $120 million in fourth-quarter 2016 and $132 million for the year versus a profit of…

Read More

OIS Index Underperforms Benchmarks in First Quarter Since Inception

In October, OIS partnered with EyeQ Research to launch the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our sector. Our goal is to highlight ophthalmology investment performance, in absolute terms and compared with broader biotech and medical device industries, as well as the stock market as a whole.…

Read More

After Stunning Phase III Results, Ophthotech Seeks a Path Forward

Eye On Innovation Article - After stunning Phase 3 results, Ophthotech seeks a path forward - Healthegy

After disappointing Phase III results of Fovista (pegpleranib) in combination with Lucentis (ranibizumab, Genentech) sent its stock reeling, Ophthotech Corporation is reevaluating not only the trial data but also how the results will impact ongoing Fovista combination trials as well as its overall business. And while Ophthotech may have the equivalent of financial pneumonia, if…

Read More

Eye on Five – November Edition

OIS - Eye on Five

Trump Bump Fuels Biotech, Pharma Stocks Pharma and biotech stocks surged in the week after Donald Trump’s election, with the OIS Index jumping 13% and the NASDAQ Biotech Index surging 11.2%. The gains have since trailed off, but the latter index was still up 8% for November at month-end. Three anticipated policy changes have fueled…

Read More

Welcome to OIS@AAO 2016

Welcome to OIS@AAO 2016 - Eye On Innovation Article - OIS - Healthegy

More than 800 leaders of the ophthalmology industry will convene Thursday at the Hyatt Regency Chicago Hotel ballroom for our largest Ophthalmology Innovation Summit of the year. This is the 8th OIS@AAO held prior to the annual meeting of the American Academy of Ophthalmology. Registration and check-in for those attending the Breakfast Breakout Sessions will…

Read More

What Does the Leadership Shuffle Mean for Ophthalmology?

A Look at Recent Leadership Changes in Ophthalmology - OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 073″] The combination of Pfizer and Allergan certainly creates some waves in ophthalmology. But did these choppy waters have anything to do with recent leadership changes in the sector? Transcript Tom Salemi: Hi, everyone, welcome back to the OIS Podcast. This is Tom Salemi, your host. Thanks a lot for joining…

Read More

EyeGate Finds New Paths to Dollars, Deal

OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 072″] EyeGate Pharmaceuticals had hit a wall. Its venture investors were tapped out, and the company needed capital to continue running clinical trials on its lead product. CEO Stephen From turned to the public markets, leading the company through a unique – and small IPO. With $4 million from the offering,…

Read More

Exploring Novartis’ Interest in Medtech

Reza Zadno, PhD, EIR at InterWest Partners explains his new role at the Novartis Venture Fund. He’ll advise the pharma company on where to commit its considerable dollars in Medtech. Novartis, which own Alcon, historically has invested in Medtech and has done a nice job investing in companies like Zadno’s Visiogen. Speaking With: Reza Zadno…

Read More

Protecting & Monetizing IP – A Primer for Early Stage Entrepreneurs

Moderator: Casey McGlynn J. Casey McGlynn formed the Life Sciences Group at Wilson Sonsini Goodrich & Rosati in 1990. It is a nationally recognized practice representing startups and emerging growth companies in the life sciences field–Medical Devices, Digital Health, Diagnostics and Biotechnology. View Full Profile Panelists: Mark S. Blumenkranz, MD Mark S. Blumenkranz, MD, MMS,…

Read More

Ophthalmic Innovation 2015 – “A View from the NEI”

Participant: Paul A. Sieving, MD, PhD Dr. Sieving became Director of the National Eye Institute after serving as the Paul R. Lichter Professor of Ophthalmic Genetics and founding director of the Center for Retinal and Macular Degeneration at the University of Michigan. View Full Profile

Read More